Inactive Instrument

NuGenerex Immuno-Oncology, Inc.

Equities

NUGX

US67053X1028

Biotechnology & Medical Research

Nugenerex Immuno-Oncology, Inc. Reports Earnings Results for the Second Quarter Ended January 31, 2021

March 12, 2021 at 03:05 pm

NuGenerex Immuno-Oncology, Inc. announced earnings results for the second quarter ended January 31, 2021. For the second quarter, the company announced operating loss was USD 1.832 million compared to USD 83,550 a year ago. Net loss was USD 2.081 million compared to USD 292,367 a year ago. Basic loss per share from continuing operations was USD 0.01. For the half year, operating loss was USD 3.331 million compared to USD 367,119 a year ago. Net loss was USD 3.820 million compared to USD 775,631 a year ago. Basic loss per share from continuing operations was USD 0.01.

Latest news about NuGenerex Immuno-Oncology, Inc.

Nugenerex Immuno-Oncology, Inc. Reports Earnings Results for the Third Quarter Ended April 30, 2021	14/06/21	CI
NuGenerex Immuno-Oncology, Inc. has completed an IPO in the amount of $50.000004 million.	19/05/21	CI
NuGenerex Immuno-Oncology, Inc. Submits Protocol, Data, and Manufacturing Information to FDA in Advance of the IND Submission	12/04/21	CI
Nugenerex Immuno-Oncology, Inc. Reports Earnings Results for the Second Quarter Ended January 31, 2021	12/03/21	CI
Nugenerex Immuno-Oncology, Inc. and Generex Biotechnology Corporation Signs an Extension for the Receipt of the USD 5,000,000.00 Upfront Licensing Fee Payment	17/12/20	CI
NuGenerex to Seek Merger or Acquisition Opportunities	15/12/20	CI
Generex Biotechnology Corporation and Nugenerex Immuno-Oncology Grants Licensing Rights to Bintai Healthcare Sdn Bhd	25/11/20	CI
Generex Biotechnology Corporation and NuGenerex Immuno-Oncology Ii-Key-SARS-CoV-2 Vaccine Partner Bintai Kinden Executes its Exclusive Distribution & Licensing Option for Australia and New Zealand	23/11/20	CI
Generex Biotechnology Corporation and NuGenerex Immuno-Oncology, Inc. Sign Distribution and Licensing Agreement with Bintai Healthcare SDN BHD	09/10/20	CI
NuGenerex Immuno-Oncology Announces Closing of a Licensing & Distribution Agreement with Bintai Kinden to Advance the Clinical Development & Commercialization of Ii-Key-SARS-CoV-2 Coronavirus Vaccine for Global Markets	07/10/20	CI
Bintai Healthcare Sdn Bhd Enters into A Distribution and Licensing Agreement with Generex Biotechnology Corporation and Its Majority Owned Subsidiary, Nugenerex Immuno-Oncology, Inc	06/10/20	CI
Generex Biotechnology Corporation and NuGenerex Immuno-Oncology, Inc. Sign Agreement with Bintai Kinden Corporation of Malaysia for the Development and Commercialization of the II-Key-SARS-CoV-2 Coronavirus Vaccine	24/09/20	CI
NuGenerex Immuno-Oncology, Inc. has filed an IPO in the amount of $1 million.	14/09/20	CI
Bintai Kinden Corporation Berhad Announces Memorandum of Understanding with Nugenerex Immuno-Oncology on New Business Opportunity (COVID-19 Vaccine)	17/08/20	CI
Nugenerex Immuno-Oncology Closes $50 Million Financing Facility	15/07/20	CI
NuGenerex Immuno-Oncology Announces Plans to Address the New Emerging Pandemic Threat from G4 EA H1N1 Swine Influenza Virus Using Ii-Key-H1 Peptide Vaccine	02/07/20	CI
NuGenerex Immuno-Oncology Announces Board of Directors	01/07/20	CI
NuGenerex Immuno-Oncology Seeks Acquisition and Investment Opportunities	17/06/20	CI
NuGenerex Immuno-Oncology Advances COVID-19 Vaccine Program with the Manufacturing of Patent-Pending Ii-Key-SARS-CoV-2 Peptides	22/05/20	CI
NuGenerex Immuno-Oncology Announces Publication of Positive Results of the AE37 Phase IIb Breast Cancer Trial	28/04/20	CI
NuGenerex Immuno-Oncology Appoints Independent Director S. Gail Eckhardt, Md to Board of Directors	02/03/20	CI
Generex Biotechnology Subsidiaries Nugenerex Immuno-Oncology and Nugenerex Diagnostics Working to Address the Coronavirus Pandemic and Emerging Risk of Avian Flu Using Ii-Key Peptide Vaccines	06/02/20	CI
NuGenerex Immuno-Oncology Announces Board Changes	05/02/20	CI
Nugenerex Immuno-Oncology Announces Board Changes	30/01/20	CI
NuGenerex Immuno-Oncology Appoints Marvin S. Hausman to Board of Directors	11/12/19	CI

Chart NuGenerex Immuno-Oncology, Inc.

Duration

Period

More charts

Company Profile

NuGenerex Immuno-Oncology, Inc. is a biotechnology company. The Company is focused on the modulation of the immune system and activation of T cells to treat cancer. It is engaged in developing immunotherapeutic products and vaccines based on its patented platform technology, Ii-Key. The Ii-Key is a peptide derived from the major histocompatibility complex (MHC) Class II associated invariant chain (Ii) that regulates the formation, trafficking, and antigen-presenting functions of MHC class II complexes, essential for the activation of T cells in the immune response. The Company's lead immunotherapy product candidate is AE37, an Ii-Key-HER2 peptide vaccine for breast, prostate, and bladder cancer. AE37, an Ii-Key-HER2 vaccine that contains the HER2/neu antigenic peptide linked to the Ii-Key to enhance immune stimulation against HER2, which is expressed in numerous cancers.

Sector

Biotechnology & Medical Research

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	+3.91%	109B
REGENERON PHARMACEUTICALS, INC.	+10.87%	105B
ARGENX SE	+1.28%	22.25B
BIONTECH SE	-13.14%	22.09B
GENMAB A/S	-7.05%	18.68B
WUXI APPTEC CO., LTD.	-38.36%	17.58B
BEIGENE, LTD.	-10.66%	16.85B
NEUROCRINE BIOSCIENCES, INC.	+3.75%	13.76B
SAREPTA THERAPEUTICS, INC.	+36.70%	12.46B

Bio Therapeutic Drugs